Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission
Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.